LexisNexis® Legal Newsroom
Pa. Risperdal Off-Label Trial Ends With Nonsuit For Janssen

PHILADELPHIA - (Mealey's) A Pennsylvania state court judge on June 14 granted Janssen Pharmaceutica Inc.'s motion for a nonsuit of the state government's third-party payer suit alleging that the drug company's off-label marketing of its atypical antipsychotic drug Risperdal resulted in...

West Virginia High Court Vacates $4.47M Judgment; FDA Warning Letters Not Matter Of Law

CHARLESTON, W.Va. -- (Mealey's) The West Virginia Supreme Court of Appeals on Nov. 18 reversed a $4,475,000 consumer law judgment against Johnson & Johnson concerning the marketing of Risperdal and Duragesic after agreeing with the defendant that the judge in a bench trial improperly relied on...

Arkansas High Court Reverses $1.2B Risperdal Verdict For State Law Violations

LITTLE ROCK, Ark. — (Mealey’s) In a 4-3 decision, the Arkansas Supreme Court on March 20 reversed a $1.2 billion verdict against Janssen Pharmaceuticals for violating state law in its marketing of the antipsychotic drug Risperdal ( Ortho-McNeil-Janssen Pharmaceuticals, Inc., et al. v. State...